Shamrock Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Shamrock Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-25	Closed	-$10K	–	288
2016 Q3	$10K	Sell	25 -25	-50%	-$10K	0.01%	227
2016 Q2	$17K	Buy	+50	New	+$19.3K	0.01%	190
2016 Q1	–	Sell	-100	Closed	-$54K	–	272
2015 Q4	$54K	Buy	+100	New	+$54.2K	0.03%	136
2015 Q3	–	Sell	-250	Closed	-$128K	–	279
2015 Q2	$128K	Buy	250 +50	+25%	+$24.4K	0.06%	101
2015 Q1	$90K	Buy	200 +50	+33%	+$21.2K	0.04%	116
2014 Q4	$62K	Buy	150 +50	+50%	+$19.7K	0.02%	104
2014 Q3	$36K	Buy	+100	New	+$33.5K	0.01%	160

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Shamrock Asset Management's REGN Position: Q4 2016 in Review

Shamrock Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 25 shares — an estimated $10K sold.

Shamrock Asset Management first reported a position in REGN in Q3 2014 and held it in 7 quarters. The position peaked at $128K in Q2 2015. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

Shamrock Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Shamrock Asset Management sold 25 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $10K.
Shamrock Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Shamrock Asset Management's Regeneron Pharmaceuticals position peaked at $128K in Q2 2015.
576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Shamrock Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.